The BCL2 inhibitor (BCL2i) venetoclax has shown significant benefical activity in CLL and acute myeloid leukemia (AML) [143,144,145], but the therapeutic effects in DLBCL are still under investigation. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.